OakChart

Travere Therapeutics Inc

TVTXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

52.04+0.05 (0.10%)
2026-11-12 04:32 CET
Market cap
4,995.43 USD m
Revenue, TTM
651.03 USD m
Net income, TTM
-154.42 USD m
Free cash flow, TTM
176.96 USD m
EPS diluted, TTM
-1.66
P/E
-
Compare

Price

TVTX against its 20, 50 and 200-day averages
2050200miss
30.0040.0050.0060.0070.004.5M9.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TVTXclose 52.0420-day 50.9150-day 56.56200-day 47.4952.0452w high

24.3% under the 52-week high of 68.73 on 11 Sep 2026. 52-week low 22.59 on 13 Jan 2026. Last 15 sessions, 19.2% high to low

Volume 0.43× normal · the line is the 50-bar volume average

Profile

TVTX
52-week range, 64% of the way up
22.5968.73

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

IndexRUT
Employees497
IPOOct 06, 2003
Beta1.11
ATR, 14d2.56
Rel volume0.43
Short float10.26%
Insider own2.96%
Inst own112.35%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap5.00B
Enterprise Value5.14B
Income-154.42M
Sales651.03M
Book/sh0.24
Cash/sh4.92
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees497
IPOOct 06, 2003

Ratios

P/E-
Forward P/E17.34
PEG-
P/S7.67
P/B220.46
P/C10.59
P/FCF28.23
EV/EBITDA158.63
EV/Sales7.89
Quick Ratio2.95
Current Ratio3.00
Debt/Eq27.29
LT Debt/Eq27.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.66
EPS next Y3.00
EPS next Q0.44
EPS this Y-173.46%
EPS next Y478.50%
EPS next 5Y-
EPS past 3/5Y49.47% 30.85%
Sales past 3/5Y64.89% 19.87%
EPS Y/Y TTM-58.47%
Sales Y/Y TTM49.38%
EPS Q/Q-357.49%
Sales Q/Q36.22%
EarningsNov 02 AMC
EPS/Sales Surpr.-890.99% 14.99%

Ownership

Insider Own2.96%
Insider Trans-31.75%
Inst Own112.35%
Inst Trans4.18%
ROA-22.27%
ROE-321.22%
ROIC-24.42%
Gross Margin90.43%
Oper. Margin-3.13%
Profit Margin-23.72%
SMA202.23%
SMA50-7.99%
SMA2009.59%
Trades-

Technical

Shs Outstand95.67M
Shs Float93.16M
Short Float10.26%
Short Ratio5.23
Short Interest9.56M
52W High68.73 -24.28%
52W Low22.59 130.37%
Volatility4.51% 5.18%
ATR (14)2.56
RSI (14)48.47
Beta1.11
Rel Volume0.43
Avg Volume1.83M
Volume780,594

Performance

Perf Week-0.72%
Perf Month0.46%
Perf Quarter-15.29%
Perf Half Y16.81%
Perf YTD36.19%
Perf Year44.12%
Perf 3Y832.62%
Perf 5Y73.29%
Perf 10Y145.94%
Recom1.13
Target Price73.43
Prev Close51.99
Price52.04
Change %0.10%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Apr 14, 2026UpgradePPiper SandlerNeutral → Overweight$49-5.8%
Oct 31, 2025ReiteratedCCitigroupBuy$34 → $48-7.8%
Jun 11, 2025ResumedHH.C. WainwrightBuy$30-42.4%
Jun 11, 2025ReiteratedCCitigroupBuy$35 → $32-38.5%
Jan 10, 2025InitiatedCCantor FitzgeraldOverweight
Oct 21, 2024UpgradeWWells FargoEqual Weight → Overweight$9 → $27-48.1%
Oct 16, 2024InitiatedBScotiabankSector Outperform
Sep 09, 2024UpgradeGGuggenheimNeutral → Buy$25-52.0%
Mar 27, 2024DowngradeGGuggenheimBuy → Neutral
Dec 05, 2023UpgradeCCitigroupNeutral → Buy$7 → $10-80.8%

Peers

Mkt cap
TickerCompanyMkt cap
VERAVera Therapeutics Inc2.20B
VRTXVertex Pharmaceuticals Inc138.69B
MAZEMaze Therapeutics Inc2.01B
MIRMMirum Pharmaceuticals Inc6.18B
PTCTPTC Therapeutics Inc5.42B
ARDXArdelyx Inc786.79M
BMRNBiomarin Pharmaceutical Inc11.30B
RYTMRhythm Pharmaceuticals Inc7.78B
NVSNovartis AG ADR293.47B
AKBAAkebia Therapeutics Inc159.30M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Dube Eric MCHIEF EXECUTIVE OFFICEROct 15 '26Option Exercise12.15243,7352,961,597676,621Oct 19 04:05 PM
Dube Eric MCHIEF EXECUTIVE OFFICEROct 15 '26Sale53.82243,73513,116,671432,886Oct 19 04:05 PM
ERIC DUBEDirectorOct 15 '26Proposed Sale53.27243,73512,983,763Oct 15 04:40 PM
ROTE WILLIAM E.Chief Research OfficerSep 16 '26Option Exercise21.29112,8502,402,186211,047Sep 17 09:35 PM
ROTE WILLIAM E.Chief Research OfficerSep 15 '26Option Exercise21.5778,6501,696,864194,395Sep 17 09:35 PM
ROTE WILLIAM E.Chief Research OfficerSep 16 '26Sale63.33112,8507,146,64498,197Sep 17 09:35 PM
ROTE WILLIAM E.Chief Research OfficerSep 15 '26Sale62.2596,1985,988,75398,197Sep 17 09:35 PM
Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSep 16 '26Option Exercise14.19172,7172,451,533289,783Sep 17 09:35 PM
Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSep 15 '26Option Exercise18.3177,1901,413,039219,256Sep 17 09:35 PM
Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSep 17 '26Option Exercise22.408,282185,517125,348Sep 17 09:35 PM
Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSep 16 '26Sale63.43172,71710,956,088117,066Sep 17 09:35 PM
Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSep 15 '26Sale62.26102,1906,362,825117,066Sep 17 09:35 PM
Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSep 17 '26Sale65.078,282538,917117,066Sep 17 09:35 PM
Inrig JulaEVP, Head of R&D & CMOSep 15 '26Option Exercise8.9332,395289,287145,165Sep 17 09:33 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 200
  • Travere Crashed Into Its 200-Day Line And Then Reversed Higher; Here's Why (Investor's Business Daily) +6.09%
  • Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
  • Travere: Q3 Earnings Snapshot (Associated Press)
  • Travere's FILSPARI Tops $200 Million As Revenue Beats, But A Deal Charge Drives An EPS Miss And Softer New-Patient Starts Cloud The Ramp (Earnings Whispers)
  • Travere Therapeutics Reports Third Quarter 2026 Financial Results (Business Wire)
  • Travere's FSGS Launch Faces Its Durability Test As Stock Slides Toward Post-Earnings Lows (Earnings Whispers)
  • Travere Therapeutics to Report Third Quarter 2026 Financial Results (Business Wire)
  • Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy (Business Wire)
  • Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Travere to Present New Data Supporting FILSPARI (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 (Business Wire)
  • Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sparsentan) in Focal Segmental Glomerulosclerosis (Business Wire)
  • Travere Therapeutics Announces Planned Chief Executive Officer Transition (Business Wire)
  • Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum (Business Wire)
  • Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-02-0.550-0.056-0.550224.56195.2911
2026Q22026-08-04-0.370-0.135-0.372169.58157.2711
2026Q12026-05-04-0.400-0.242-0.398127.2136.2311
2025Q42026-02-190.0300.002-0.244129.69144.5512
2025Q32025-10-300.280-0.3040.251164.86105.2111
2025Q22025-08-06-0.140-0.312-0.14394.8499.4710
2025Q12025-05-01-0.470-0.567-0.46775.8677.2710
2024Q42025-02-20-0.730-0.562-0.72573.5573.0813
2024Q32024-10-31-0.700-0.669-0.70562.9060.8713
2024Q22024-08-01-0.910-0.791-0.90952.1850.4013
2024Q12024-05-06-1.760-0.940-1.76439.9843.4614
2023Q42024-02-15-1.180-1.158-1.18045.0641.6915
2023Q32023-11-071.970-1.064-0.98633.9357.339
2023Q22023-08-03-1.130-1.089-1.12757.0153.5614
2023Q12023-05-04-1.270-1.201-1.26656.9950.6111
2022Q42023-02-23-1.030-1.134-1.02555.8753.0110

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.120-2.836-3.458175.34174.68
2020FY-3.560-1.446-3.564198.32198.95
2021FY-3.010-3.012-3.010227.49225.72
2022FY-4.370-4.476-4.368212.02208.36
2023FY-1.500-1.618-4.543145.24195.51
2024FY-4.080-3.647-4.076226.71230.97
2025FY-0.290-0.335-0.290490.73499.28
2026FY--0.793--768.82
2027FY-3.002--1,147
2028FY-4.310--1,438
2029FY-5.322--1,720
2030FY-6.022--2,025

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0514103247.51218.33297
2026Q4S2026-11-031493244.87211297
2026Q4S2026-11-021423231.72203.78266
2026Q4S2026-10-281423231.72203.78266
2026Q4S2026-10-271422234.12203.78269.91
2026Q4S2026-10-221421234.41203.78269.91
2026Q4S2026-10-201421234.41203.78269.91
2026Q4S2026-10-191411230.3180.68269.91
2026Q4S2026-10-161494230.12180.68269.91
2026Q4S2026-10-0514103232.12180.68274.78
2026Q4S2026-09-2214103232.12180.68274.78
2026Q4S2026-09-0714103232.12180.68274.78
2026Q4S2026-08-1414103232.12180.68274.78
2026Q4S2026-08-131393231.37180.68274.78

Estimate history

EPS, annual-1.54-2.539-3.458-3.564-3.01-4.368-4.543-4.076-0.563-1.6592
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.705-0.725-0.467-0.1430.251-0.244-0.398-0.372-0.645
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual154.937164.246175.338198.321227.49109.46145.238233.175490.728651.03
Period201720182019202020212022202320242025TTM
Sales, quarterly62.89874.78781.732114.449164.859129.689127.199169.584224.563
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual39.37441.3943.08952.24862.49164.29175.36787.45390.92395.673
Period201720182019202020212022202320242025MRQ
Shares, quarterly77.90987.45388.78789.10289.45790.92392.40494.17595.673
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue651.03490.73233.18145.24109.46227.49198.32175.34164.25
Cost of Goods Sold Incl. D&A62.3371.0851.3049.9825.1433.4028.5625.6423.55
Gross Profit588.71419.65181.8895.2684.32194.09169.76149.70140.69
Selling, General and Administrative Excl. Other609.09482.47438.06472.00404.13333.59245.13249.51209.38
Research and Development245.55206.01217.50237.73221.07208.85130.61139.80122.78
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-20.38-62.82-256.18-376.74-319.81-139.50-75.38-99.81-68.69
Interest Expense8.8710.7511.1811.3311.0120.1419.0518.839.81
Unusual Expense153.120.0067.6411.397.5822.26100.7937.5528.39
Net Income Before Taxes-159.72-49.27-320.51-376.11-331.15-179.68-188.79-146.45-101.87
Income Taxes-5.300.990.120.220.310.41-19.36-0.020.81
Consolidated Net Income-154.42-50.26-320.63-376.33-331.47-180.09-169.43-146.43-102.68
Net Income From Continuing Operations-154.42-50.26-320.63-376.33-331.47-180.09-169.43-146.43-102.68
Net Income-154.42-50.26-321.55-337.40-278.48-180.09-169.43-146.43-102.68
EPS (Recurring)-0.50-0.56-3.48-4.44-4.28-2.75-2.08-2.84-2.05
EPS (Basic, Before Extraordinaries)-1.66-0.56-4.08-4.54-4.37-3.01-3.56-3.46-2.54
EPS (Diluted)-1.66-0.56-4.08-4.54-4.37-3.01-3.56-3.46-2.54
EBITDA32.40-2.08-212.63-338.21-299.09-112.89-49.59-79.40-50.02
Non-Operating Income (Expense)22.6524.3014.5023.367.252.226.429.745.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense57.5435.4529.1634.9530.1322.4617.2415.4115.62
Price To Sales Ratio8.566.955.894.6012.258.166.533.435.57
Gross Margin90.4385.5178.0065.5977.0385.3285.6085.3885.66
Operating Margin-3.13-12.80-109.87-259.40-292.17-61.32-38.01-56.92-41.82
Net Margin-23.72-10.24-137.90-232.31-254.41-79.16-85.43-83.51-62.51
Shares Outstanding95.6790.9287.4575.3764.2962.4952.2543.0941.39
Market Capitalization4,995.434,995.431,516.14675.561,349.571,900.471,391.42610.00933.44

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue224.56169.58127.20129.69164.86114.4581.7374.79
Cost of Goods Sold Incl. D&A8.076.4127.1620.6917.3715.5417.4814.65
Gross Profit216.50163.18100.04109.00147.4998.9164.2560.14
Selling, General and Administrative Excl. Other171.49159.22136.95141.43122.56111.56106.92119.47
Research and Development70.3060.2857.0957.8751.8949.3646.8962.07
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income45.013.95-36.91-32.4324.93-12.65-42.67-59.33
Interest Expense2.142.132.302.302.752.852.862.82
Unusual Expense113.1140.010.000.000.000.000.001.40
Net Income Before Taxes-66.93-35.00-36.72-21.0725.71-12.73-41.19-60.34
Income Taxes-5.89-0.20-0.120.920.010.020.04-0.07
Consolidated Net Income-61.04-34.80-36.60-21.9925.71-12.76-41.23-60.27
Net Income From Continuing Operations-61.04-34.80-36.60-21.9925.71-12.76-41.23-60.27
Net Income-61.04-34.80-36.60-21.9925.71-12.76-41.23-60.26
EPS (Recurring)0.19-0.07-0.40-0.240.25-0.14-0.47-0.71
EPS (Basic, Before Extraordinaries)-0.65-0.37-0.40-0.240.29-0.14-0.47-0.73
EPS (Diluted)-0.65-0.37-0.40-0.240.25-0.14-0.47-0.73
EBITDA50.218.19-11.70-14.2940.721.37-29.87-47.24
Non-Operating Income (Expense)3.313.192.4913.663.532.764.343.21
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense18.5217.2112.769.068.908.419.089.21
Price To Sales Ratio8.568.985.097.035.633.945.796.21
Gross Margin96.4196.2278.6584.0589.4686.4278.6180.42
Operating Margin20.042.33-29.02-25.0015.12-11.05-52.21-79.34
Net Margin-27.18-20.52-28.78-16.9515.59-11.14-50.44-80.58
Shares Outstanding95.6794.1792.4090.9289.4689.1088.7987.45
Market Capitalization4,995.435,282.932,740.503,418.742,130.411,314.311,590.221,516.14

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments322.80370.70566.85450.25552.88361.59398.52471.54300.63
Short Term Receivables81.4329.4221.1816.6516.1633.0718.0514.4913.87
Inventories5.886.209.414.527.317.616.085.625.35
Other Current Assets27.4610.3819.3415.026.478.146.414.035.95
Total Current Assets437.56416.70616.77486.44582.83410.41429.06495.68325.81
Net Property, Plant & Equipment14.6019.6325.5430.0534.3035.099.893.153.23
Total Investments and Advances0.000.000.000.000.000.000.0015.000.00
Intangible Assets113.87103.97104.4497.07148.44154.12158.14187.63185.75
Deferred Tax Assets-------32.7116.81
Other Assets39.1653.8242.1659.0311.077.817.717.715.56
Total Assets605.19594.12788.91672.59776.63607.44604.80741.87537.16
Short Term Debt Incl. Current Port. of LT Debt5.8874.084.914.433.910.362.6122.460.00
Accounts Payable24.8023.5341.6717.2915.1412.1326.616.9518.94
Other Current Liabilities129.23103.13131.32120.44105.0480.1766.2275.2166.73
Total Current Liabilities159.90200.75177.91142.16124.0992.6695.45104.6285.67
Long Term Debt322.86327.50399.88403.06258.08243.68212.25195.0945.08
Provision for Risks Charges0.000.000.000.000.000.000.0073.6580.90
Deferred Tax Liabilities-------32.7116.81
Other Liabilities7.606.8010.3284.5292.3659.8975.9017.5515.57
Total Liabilities490.36535.05588.10629.73474.52396.23383.60423.61244.02
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity114.8359.08200.8142.85302.11211.21221.20318.25293.13
Total Shareholders Equity114.8359.08200.8142.85302.11211.21221.20318.25293.13
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity114.8359.08200.8142.85302.11211.21221.20318.25293.13
Total Liabilities & Stockholders Equity605.19594.12788.91672.59776.63607.44604.80741.87537.16
Book Value Per Share1.260.682.660.674.834.045.137.697.44
Tangible Book Value Per Share0.01-0.511.28-0.842.461.091.463.162.73
Full-Time Employees497385380462310262221214173
Price to Book Ratio220.46-44.562.4113.406.426.742.772.942.72
Return on Assets-8.38-46.37-51.50-45.74-26.02-27.95-21.75-16.06-10.81
Return on Equity-57.80-246.75-308.90-192.18-70.17-78.37-54.29-33.59-19.88
Return on Invested Capital-11.48-83.18-56.17-62.45-32.15-37.25-33.78-20.00-17.66
Quick Ratio2.702.043.413.394.644.354.434.683.74
Current Ratio2.742.083.473.424.704.434.504.743.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-146.22-50.26-328.08-331.00-256.91-180.09-169.43-146.43-102.68
Depreciation52.7860.7443.5538.5320.7226.6225.7920.4118.67
Other Funds (Non Cash)239.4041.30110.0737.9249.0358.70126.9465.1247.98
Funds from Operations145.9651.78-174.46-254.55-187.17-94.77-16.70-60.89-36.03
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital30.63-14.00-63.02-25.480.8879.98-26.042.6811.07
Income Taxes Payable-0.85-------
Cash from Operating Activities176.5937.78-237.47-280.02-186.29-14.79-42.74-58.21-24.96
Capital Expenditures-90.86-58.16-36.21-42.26-28.56-24.15-24.57-15.56-19.70
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-204.7586.45200.58-109.37-3.40-113.4758.5235.43-183.59
Purchase of Investments-451.24-237.14-125.76-443.94-385.39-547.08-214.96-223.71-346.35
Sale Or Maturity of Investments246.48323.60326.33334.57381.99433.60273.48259.14162.75
Other Uses-113.52-0.40-65.040.00-0.600.00-95.280.000.00
Other Sources-0.070.000.00207.400.000.000.000.000.00
Cash from Investing Activities-409.2027.8999.3355.78-32.55-137.62-61.3319.86-203.29
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock90.0237.54141.52222.2327.11239.89137.461.6215.89
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock90.0237.54141.52222.2327.11239.89137.461.6215.89
Proceedsfrom Stock Options2.792.79137.07218.9922.52227.05133.570.000.00
Issuance or Reduction of Debt, Net157.77-68.900.000.0095.040.000.000.00226.98
Change in Long Term Debt157.77-68.900.000.0095.040.000.000.00226.98
Issuance of Long Term Debt508.650.000.000.00306.370.000.000.00267.18
Reduction of Long Term Debt-350.88-68.900.000.00-211.320.000.000.00-40.20
Net Financing Active Other Cash Flow-2.10-2.10-2.10-3.48-4.58-8.20-9.75-3.69-11.01
Other Financing Activities Uses-2.10-2.10-2.10-3.48-4.58-8.20-9.75-5.47-12.72
Cash from Financing Activities245.69-33.47139.42218.75117.57231.68127.71-2.08231.86
Exchange Rate Effect-0.462.29-0.911.98-2.791.71-1.31-0.01-0.14
Net Change in Cash12.6134.500.36-3.51-104.0680.9822.34-40.443.48
Free Cash Flow176.9637.78-237.47-280.69-186.48-19.89-49.51-58.41-25.68
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow31.4990.22-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments471.82489.18264.68322.80254.53319.54
Short Term Receivables110.3382.9488.5081.4384.4840.22
Inventories10.527.836.365.885.554.09
Other Current Assets40.7835.1933.1527.4626.5515.72
Total Current Assets633.45615.14392.68437.56371.11379.57
Net Property, Plant & Equipment10.5311.9813.2914.6015.7816.90
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets164.11131.52110.04113.87109.44105.61
Other Assets40.1440.7339.1739.1642.2553.24
Total Assets848.23799.36555.19605.19538.58555.31
Short Term Debt Incl. Current Port. of LT Debt6.316.166.025.885.7374.43
Accounts Payable15.287.5012.9124.8018.2319.13
Other Current Liabilities189.32138.37106.51129.23111.1195.97
Total Current Liabilities210.91152.03125.44159.90135.07189.54
Long Term Debt609.84610.74321.64322.86324.01325.14
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities4.8912.079.387.605.937.88
Total Liabilities825.64774.84456.46490.36465.02522.56
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity22.5824.5298.73114.8373.5632.75
Total Shareholders Equity22.5824.5298.73114.8373.5632.75
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity22.5824.5298.73114.8373.5632.75
Total Liabilities & Stockholders Equity848.23799.36555.19605.19538.58555.31
Book Value Per Share0.240.261.071.260.820.37
Tangible Book Value Per Share-1.48-1.14-0.120.01-0.40-0.82
Full-Time Employees---497--
Price to Book Ratio220.4653.1723.5246.4765.0340.03
Return on Assets-22.27-9.99-8.27-8.38-16.98-30.55
Return on Equity-321.22-236.35-69.38-57.80-410.78-705.73
Return on Invested Capital-9.65-5.48-8.71-5.026.47-3.56
Quick Ratio2.953.993.082.702.711.98
Current Ratio3.004.053.132.742.752.00

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-52.84-34.80-36.60-21.9925.71-12.76
Depreciation5.204.2325.2118.1415.7914.02
Other Funds (Non Cash)151.2660.1416.1411.8610.159.36
Funds from Operations103.6229.574.758.0151.6510.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.4228.50-45.1252.67-37.33-5.64
Cash from Operating Activities98.2058.07-40.3760.6814.324.98
Capital Expenditures-28.75-21.07-22.18-18.86-15.19-12.32
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments22.24-185.2243.73-85.50101.7817.02
Purchase of Investments-56.67-221.58-5.05-167.93-4.85-64.37
Sale Or Maturity of Investments78.9136.3748.7882.42106.6281.40
Other Uses-113.110.000.00-0.400.000.08
Other Sources0.000.000.00-0.070.000.06
Cash from Investing Activities-119.63-206.2921.55-104.8486.594.85
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock27.8930.204.7327.204.092.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock27.8930.204.7327.204.092.00
Proceedsfrom Stock Options0.000.000.002.790.000.00
Issuance or Reduction of Debt, Net-0.08157.840.000.00-68.900.00
Change in Long Term Debt-0.08157.840.000.00-68.900.00
Issuance of Long Term Debt-0.08508.730.000.000.000.00
Reduction of Long Term Debt0.00-350.880.000.00-68.900.00
Net Financing Active Other Cash Flow-0.53-0.53-0.53-0.53-0.53-0.53
Other Financing Activities Uses-0.53-0.53-0.53-0.53-0.53-0.53
Cash from Financing Activities27.29187.524.2026.68-65.341.48
Exchange Rate Effect-0.060.07-0.06-0.410.211.95
Net Change in Cash5.8139.37-14.67-17.8935.7813.26
Free Cash Flow98.2058.07-40.3761.0514.184.75
Price to Free Cash Flow31.4957.1468.9091.31--

Revenue breakdown

License2024: 6.47M 2025: 80.27M
Product2024: 226.71M 2025: 410.46M
United States2024: 233.18M 2025: 490.73M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.26%9.6M93.2M1.77M
2026-10-1511.93%10.9M91.5M1.63M
2026-09-3013.84%12.7M91.4M1.50M
2026-09-1514.17%13.0M91.4M1.64M
2026-08-3113.14%12.0M91.4M1.79M
2026-08-1413.07%11.9M91.4M1.87M
2026-07-3112.75%11.7M91.6M2.06M
2026-07-1513.30%12.0M90.4M2.21M
2026-06-3014.04%12.7M90.4M2.55M
2026-06-1514.87%13.4M90.3M2.28M
2026-05-2915.63%14.1M90.4M2.15M
2026-05-1515.50%14.0M90.4M2.13M
2026-04-3015.57%14.2M91.3M1.83M
2026-04-1514.03%12.7M90.7M1.77M
2026-03-3114.86%13.4M90.5M1.95M
2026-03-1314.79%13.4M90.5M2.09M
2026-02-2715.67%14.2M90.5M2.10M
2026-02-1316.81%15.2M90.5M2.08M
2026-01-3016.54%14.5M87.6M2.28M
2026-01-1517.51%15.4M87.8M2.29M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call37.5012.7016.700.002.6250.000.000.880-0.1940.016
call40.0010.3014.2010.402.2793.000.000.862-0.1840.018
call42.507.7011.600.001.9020.000.000.852-0.1510.019
call45.005.309.2015.611.6218.000.000.822-0.1380.021
call47.502.957.004.501.4051.000.000.743-0.1570.026
call50.000.954.901.701.1911,0100.000.623-0.2120.031
call52.500.453.500.901.14353.000.000.518-0.2110.032
call55.000.051.900.450.9472290.000.391-0.1760.031
call57.500.052.250.701.1927.000.000.330-0.1990.029
call60.000.051.450.501.23946.000.000.262-0.1860.026
call62.500.000.600.451.04015.000.000.148-0.1110.019
call65.000.001.150.201.1861080.000.134-0.1180.017
call67.500.001.350.151.32111.000.000.123-0.1240.017
call70.000.001.750.101.44818.000.000.115-0.1290.016
call75.000.002.100.001.6790.000.000.103-0.1380.015
call80.000.001.750.001.8861200.000.094-0.1460.014
call85.000.001.550.202.0753.000.000.088-0.1520.013
call90.000.002.150.002.2490.000.000.083-0.1570.012
call95.000.002.150.002.4090.000.000.078-0.1620.012
put37.500.001.150.002.0830.000.00-0.120-0.1900.016
put40.000.001.750.251.78578.000.00-0.138-0.1790.018
put42.500.001.550.951.49877.000.00-0.161-0.1670.020
put45.000.001.150.801.21673.000.00-0.193-0.1510.022
put47.500.051.350.301.01341.000.00-0.257-0.1510.026
put50.000.002.851.401.20427.000.00-0.377-0.2060.031
put52.500.003.908.300.58338.000.00-0.518-0.1000.032
put55.001.405.406.601.13773.000.00-0.618-0.1600.031
put57.504.007.306.301.1916.000.00-0.670-0.1930.029
put60.006.209.805.301.40413.000.00-0.755-0.1620.025
put62.508.4012.406.301.6339.000.00-0.852-0.1040.019
put65.0011.2014.900.001.8100.000.00-0.866-0.1110.017
put67.5013.5017.300.001.9330.000.00-0.877-0.1170.017
put70.0016.0019.800.002.0840.000.00-0.885-0.1220.016
put75.0021.1024.800.002.3590.000.00-0.897-0.1300.015
put80.0026.2029.800.002.6040.000.00-0.906-0.1370.014
put85.0031.2034.800.002.8270.000.00-0.912-0.1420.013
put90.0036.1039.800.003.0310.000.00-0.917-0.1470.012
put95.0041.1044.800.003.2180.000.00-0.922-0.1510.012

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-218-KCurrent report2026-09-21SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-10144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100013.12M1
2026-090066.34M13
2026-0800632.85K2
2026-070000
2026-0600725.75K2
2026-05004.58M15
2026-040011.18M16
2026-0300280.86K1
2026-02006.99M12
2026-01002.18M5
2025-12004.34M6
2025-11002.42M1

Institutional holders

Manager% owned
Jupiter Topco LLC12.18%
BlackRock, Inc.8.63%
FMR LLC6.23%
BANK OF AMERICA CORP /DE/4.91%
STATE STREET CORP4.58%
VANGUARD CAPITAL MANAGEMENT LLC4.42%
STATE OF WISCONSIN INVESTMENT BOARD4.38%
PERCEPTIVE ADVISORS LLC4.04%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.3.02%
ADAGE CAPITAL PARTNERS GP, L.L.C.2.76%

Funds

Fund% owned
iShares Convertible Bond ETF11.87%
Columbia Convertible Securities Fund11.67%
CALAMOS STRATEGIC TOTAL RETURN FUND9.69%
Virtus Income & Growth Fund9.41%
Virtus Convertible Fund9.14%
Calamos Market Neutral Income Fund8.07%
Miller Market Neutral Income Fund7.53%
Calamos Growth & Income Fund7.40%
State Street(R) SPDR(R) Bloomberg Convertible Securities ETF7.11%
Lord Abbett Convertible Fund6.97%

OakChart. TVTX. Cached 15 minutes.